School and Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University Hospital "G. Martino", Via Consolare Valeria SNC, 98125 Messina, Italy.
Institute of Clinical Physiology, National Research Council of Italy (IFC-CNR), Via Moruzzi 1, 56124, Pisa, Italy.
Cytokine Growth Factor Rev. 2021 Apr;58:111-113. doi: 10.1016/j.cytogfr.2020.09.001. Epub 2020 Sep 9.
Is it possible to develop a reliable, safe treatment for the widespread COVID-19 pandemic shortly? COVID-19 is characterized by a disruptive cytokine storm, quickly and often irreversibly damaging the patient's lungs, as its main target organ, leading to lung failure and death. Actual experimental therapies are trying to reduce the activation of some specific cytokines, such as IL-6, somewhat reducing the burden for the patient. However, they are often unable to block the whole storm occurring at the cytokine level. In presence of the cytokine storm, especially in severe patients, antagomiRs, already demonstrated to be efficient and secure in cardiovascular disease, could represent a useful alternative to such treatment, customizable upon the disease specificities and applicable to other coronaviruses possibly associated with such clinical manifestations, while a reliable, efficient vaccine is being distributed.
短期内能否开发出一种可靠、安全的治疗广泛流行的 COVID-19 的方法？COVID-19 的特征是破坏性的细胞因子风暴，迅速且经常不可逆转地损害患者的肺部作为其主要靶器官，导致肺衰竭和死亡。实际的实验性治疗方法试图减少某些特定细胞因子的激活，如 IL-6，从而在一定程度上减轻患者的负担。然而，它们往往无法阻止细胞因子水平上发生的整个风暴。在细胞因子风暴的情况下，特别是在重症患者中，已经在心血管疾病中证明有效的和安全的抗 miRNA 可能是这种治疗的一种有用替代方法，可根据疾病的特点进行定制，并适用于其他可能与这种临床表现相关的冠状病毒，同时可靠、有效的疫苗正在分发。
